Clay B. Siegall Ph.D is the President, Chief Executive Officer and Chairman of the Board of Seattle Genetics a company he co-founded in 1998. He built the company on a sound determination to help others, solid innovative scientific research, and cutting edge drug development. Seattle Genetics has stood in the forefront with its antibody-drug conjugates (ADCs) and under Dr. Siegall’s leadership, helped Seattle Genetics secure an FDA Approval of ADCETRIS (brentuximab vedotin) in 2011 the company’s first product which is now a global brand.
In collaboration with Takeda Pharmaceutical Company the brand ADCETRIS is now approved in over 60 countries. The company under the leadership of Dr. Siegall has entered into multiple licenses for its antibody-drug conjugates technologies. These include Genentech (Roche), Pfizer, AbbVie, and GlaxoSmithKline who have produced more than $325 million. Using Seattle Genetics technology there are more than 20 antibody-drug conjugates in clinical development and the company is creating a diverse pipeline for proprietary ADCs in cancer treatment. Prior to starting Seattle Genetics, Siegall worked with the Bristol-Myer Squibb Pharmaceutical Research Institute from 1991-1997.
He also worked at the National Cancer Institute, National Institute of Health from 1988-1991. Clay B. Siegall Ph.D., sits on the board of Directors àt Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. In 2013 Dr. Siegall received the University of Marylànd Alumnus of thé year for Computer, Math ànd Naturàl Sciences and the Pacific Northwest Ernst & Young Entrepreneur of the year. Dr. Clay B. Siegall has also authored over 70 publications and holds 15 patients. Through public and private financing Siegall has raised more than $1.2 billion for Seattle Genetics when leading their capital-raising endeavors. Clay B. Siegall is a graduate of George Washington University with a Ph.D in Genetics and the University of Maryland with a B.S in Zoology.